MedPath

Acupuncture to treat cancer related fatigue

Not Applicable
Recruiting
Conditions
Cancer fatigue
Health related quality of life
Anxiety
Depression
Alternative and Complementary Medicine - Other alternative and complementary medicine
Cancer - Breast
Mental Health - Other mental health disorders
Registration Number
ACTRN12615001152516
Lead Sponsor
Western Sydney University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
20
Inclusion Criteria

1) diagnosis of stage I, II, or III BC, who have completed breast surgery, adjuvant or neo-adjuvant chemotherapy and/or adjuvant radiotherapy between one month to 2 years prior to enrolment and who have not developed recurrent disease in the intervening period between diagnosis and study recruitment.
2) Taking adjuvant endocrine therapy and trastuzumab (Herceptin) are eligible
3) Ongoing cancer related fatigue, defined as a score of 4 or more on the fatigue sub scale of the Somatic and Psychological Health Report (SPHERE) questionnaire
4) Normal coagulation coagulation studies: PT, APTT, INR at baseline or within the previous 1 month.
5) Adequate haematological parameters at baseline or within the previous 1 month: Hb greater than 100, ANC greater than 1.0, Platelet count greater than 150.

Exclusion Criteria

1) Co-morbid medical conditions expected to cause ongoing fatigue, (e.g.co-morbidity significant anaemia (defined as Hb less than 100) or thyroid disease) as assessed by the investigator.
2) Current use of acupuncture.
3) Needle phobia.
4) Concurrent treatment with medication interfering with blood clotting or bleeding time, including heparin and fractionated heparin, vitamin K antagonists, direct thrombin inhibiitors, factor Xa inhibitors, and antiplatelet agents.
5) Life expectancy less than six months.
6) Plan for major surgery during the time of the study e.g. breast reconstruction or re-excision.
7) History of other malignany within 5 years of recruitment, other than CIN of cervix or non-melanomatous skin cancers.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath